When you have rheumatoid arthritis (RA) and take a biologic, the best source of daily-life advice, coping tips, and comfort may be people who are in the same boat. People with RA say they like to ...
A group of researchers has developed and externally validated the first-ever predictive model to help clinicians identify ...
Please provide your email address to receive an email when new articles are posted on . Patients with elderly-onset rheumatoid arthritis have similar disease activity and adverse-event risk responses ...
Pregnant women who take biologic medication for rheumatoid arthritis are not running the risk of their infant developing serious/opportunistic infections, according to research presented at the 2017 ...
Medicare coverage for biologic therapies -- a mainstay of treatment for rheumatoid arthritis-- has been in flux recently. Medicare Part B coverage for biologic therapy ended in 2004, and the Medicare ...
Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis who underwent a biologic and/or disease-modifying antirheumatic drug taper ...
Rheumatoid arthritis (RA), a chronic, progressive, hard-to-diagnose, systemic autoimmune disease that manifests primarily in the synovial membrane of the joints but also in other organs, affects ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...
The global rheumatoid arthritis drugs market was valued at US$31.27 billion in 2024 and is projected to reach US$56.62 ...
Rheumatoid arthritis (RA) inflammation attacks the tissue lining your joints and causes swelling and pain. Inflamed joint tissue breaks down and wears away. Without medications to treat and control RA ...
LONDON--(BUSINESS WIRE)--The global rheumatoid arthritis (RA) drugs market 2018-2022 is expected to post a CAGR of close to 8% during the forecast period, according to the latest market research ...